LIDDS’ Annual Report 2024 published

LIDDSSelskabsmeddelelse06.05.2025, 08.00

GOTHENBURG, SWEDEN – The 2024 Annual report of LIDDS AB (publ) is now available on the company website.

The annual report is available in Swedish in PDF format on the company website at: https://liddspharma.com/en/investors/financial-reports/.

Copies can be ordered from LIDDS AB, co Excore, Kungsportsavenyen 22, 411 36 Göteborg or by e-mail: info@liddspharma.com.

LIDDS in brief:

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.